Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

U.S. Senator Expands Opioid Probe to Distributors, Drugmakers

Reuters Staff  |  July 27, 2017

(Reuters)—U.S. Democratic Senator Claire McCaskill on Thursday expanded an investigation into the causes of the opioid crisis plaguing the country, seeking information from four more drugmakers and three drug distributors.

The top-ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee is focusing on the distribution of opioids and the efforts companies made to report and investigate the diversion of drugs for illicit use.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The investigation comes at a time when lawmakers and regulators take steps to combat the epidemic of opioid addiction, with 91 Americans dying everyday as a result of overdose, according to the U.S. Centers for Disease Control and Prevention.

McCaskill requested documents and information from opioid manufacturers Mallinckrodt Plc, Endo International Plc, Teva Pharmaceutical and Allergan Plc.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In March, McCaskill asked Johnson and Johnson, Mylan NV, Purdue Pharma, Insys Therapeutics Inc and Depomed Inc for internal estimates of the risk of abuse, addiction and overdose of opioids.

The senator also sent a request to McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, focusing on their distribution of opioid products.

McCaskill also requested for information on compensation provided that is in any way derived from revenue or profitability targets for sales of opioid products.

“We appreciate Senator McCaskill’s inquiry and look forward to thoughtfully answering her questions,” McKesson spokeswoman said in an email, adding that there was no link between the sale of controlled substances and incentive compensation for the company’s executives.

AmerisourceBergen said it would respond to the letter from the Senator, adding it provides daily reports to the regulators about the quantity, type and receiving pharmacy of every single order of controlled substances it distributes.

Endo said it received the letter and would provide the Senator with the requested information.

Cardinal Health, Mallinckrodt, Allergan and Teva did not immediately respond to request for comments.

 

Share: 

Filed under:Drug UpdatesLegal Updates Tagged with:Allergan Plc.Endo International PlcMallinckrodt Plcopioid crisisOpioid probeTeva PharmaceuticalsU.S. Democratic Senator Claire McCaskill

Related Articles

    Speak Out Rheum: How Did We Go So Wrong with Opioid Prescribing?

    November 4, 2022

    I have been listening to The Fighter Pilot Podcast because my fantasy career would have been to fly a jet fighter plane (not even remotely possible, given my constitution). I learned that when an aircraft accident occurs, a mishap board is convened, not to assign blame but to try to learn what went wrong and…

    ah_designs / shutterstock.com

    The Perils of Pain Meds Revisited

    December 18, 2018

    More than 10 years ago, I wrote a commentary in The Rheumatologist, called “Perils of Pain Meds,” about the over-prescribing of opioid analgesics for common causes of chronic noncancer pain, which was a major contributor to the opioid epidemic.1 Since that time, although there has been a greater than 20% decrease in opioid prescribing, the…

    U.S. Senator Launches Probe into 5 Top Opioid Drugmakers

    March 29, 2017

    (Reuters)—U.S. Democratic Senator Claire McCaskill sought on Tuesday details from the nation’s top opioid drugmakers on their sales and marketing practices, as lawmakers step up efforts to tackle the country’s deadly opioid crisis. The Missouri senator’s investigation comes amid an epidemic of opioid addiction, with 91 Americans dying everyday as a result of overdose, according…

    Pfizer to Buy Allergan in $160 Billion Deal

    November 24, 2015

    NEW YORK (Reuters)—Pfizer Inc. on Monday said it would buy Botox maker Allergan Plc. in a deal worth $160 billion to slash its U.S. tax bill, rekindling a fierce political debate over the financial maneuver. The acquisition, which would shift Pfizer’s headquarters to Ireland, would be the biggest-ever tax inversion. The news prompted Democratic presidential…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences